bioRxivMicrobiology
Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines
L. Wang, M. H. Kainulainen, N. Jiang, H. Di, G. Bonenfant, L. Mills, M. Currier, P. Shrivastava-Ranjan, B. M. Calderon, M. Sheth, B. R. Mann, J. Hossain, X. Lin, S. Lester, E. Pusch, J. Jones, D. Cui, P. Chatterjee, H. M. Jenks, E. Morantz, G. Larson, M. Hatta, J. Harcourt, A. Tamin, Y. Lin, , Davis
Abstract
IntroductoryThe evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the emergence of many new variant lineages that have exacerbated the COVID-19 pandemic. Some of those variants were designated as variants of concern/interest (VOC/VOI) by national or international authorities based on many factors including their potential impact on vaccines. To ascertain and rank the risk of VOCs and VOIs, we analyzed their ability to escape from vaccine-induced antibodies. The variants showed differential reductions in neutralization and replication titers by post-vaccination sera. Although the Omicron variant showed the most escape from neutralization, sera collected after a third dose of vaccine (booster sera) retained moderate neutralizing activity against that variant. Therefore, vaccination remains the most effective strategy to combat the COVID-19 pandemic.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice
K. Wu, A. Choi, … D. K. Edwards·bioRxiv·Apr 13, 2021
- SARS-CoV-2 mRNA Vaccine Induces Robust Specific and Cross-reactive IgG and Unequal Strain-specific Neutralizing Antibodies in Naïve and Previously Infected Recipients
T. M. Narowski, K. Raphel, … L. Premkumar·bioRxiv·Jun 19, 2021
- Loss of Neutralizing Antibody Response to mRNA Vaccination against SARS-CoV-2 Variants: Differing Kinetics and Strong Boosting by Breakthrough Infection
J. P. Evans, C. Zeng, … S.-L. Liu·bioRxiv·Dec 6, 2021
- Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants
A. Choi, M. Koch, … D. K. Edwards·bioRxiv·Jun 28, 2021
- mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant
V.-V. Edara, K. E. Manning, … M. S. Suthar·bioRxiv·Dec 20, 2021
- Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants
T. Tada, H. Zhou, … N. R. Landau·bioRxiv·Jul 19, 2021